Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy

Nuclear Medicine and Biology

Volumn 41, Issue S, 2014, Pages

  Gouard, S ^a,b,c   Pallardy, A ^a,b,c,d   Gaschet, J ^a,b,c   Faivre Chauvet, A ^a,b,c,d,e   Bruchertseifer, F ^f   Morgenstern, A ^f   Maurel, C ^a,b,c   Matous, E ^a,b,c   Kraeber Bodere F ^a,b,c,d,e   Davodeau, F ^a,b,c   Cherel M ^a,b,c,e  

^a Team 12   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CNRS   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e UMR INSERM U892 CNRS 6299   (France)

^f JOINT RESEARCH CENTRE   (Italy)

Author keywords

Alpha particle; Bismuth 213; CD138; Melphalan; Oncology: multiple myeloma; Radioimmunotherapy

Indexed keywords

BISMUTH; MELPHALAN; RADIOISOTOPE; SYNDECAN 1;

ANIMAL; C57BL MOUSE; CHEMORADIOTHERAPY; COMPARATIVE STUDY; FEMALE; FLUORESCENCE IMAGING; IMMUNOLOGY; MOUSE; MULTIPLE MYELOMA; PATHOLOGY; RADIOIMMUNOTHERAPY; TUMOR CELL LINE;

ANIMALS; BISMUTH; CELL LINE, TUMOR; CHEMORADIOTHERAPY; FEMALE; MELPHALAN; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; OPTICAL IMAGING; RADIOIMMUNOTHERAPY; RADIOISOTOPES; SYNDECAN-1;

EID: 84898880326     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.02.008     Document Type: Review

References (34)

1. Kyle R.A., Rajkumar S.V. Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
2. Palumbo A., Anderson K. Multiple myeloma. N Engl J Med 2011, 364:1046-1060.
3. Lonial S., Mitsiades C.S., Richardson P.G. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011, 17:1264-1277.
4. Munshi N., Anderson K. New strategies in the treatment of multiple myeloma. Clin Cancer Res 2013, 19:1-9.
5. Jacene H.A., Filice R., Kasecamp W., Wahl R.L. Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in clinical practice. J Nucl Med 2007, 48:1767-1776.
6. Garrett I.R., Dallas S., Radl J., Mundy G.R. A murine model of human myeloma bone disease. Bone 1997, 20:515-520.
7. Turner J.H., Claringbold P.G., Manning L.S., O'Donoghue H.L., Berger J.D., Glancy R.J. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation. J Natl Cancer Inst 1993, 85:1508-1513.
8. Wijdenes J., Vooijs W.C., Clement C., Post J., Morard F., Vita N., et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996, 94:318-323.
9. Supiot S., Faivre-Chauvet A., Couturier O., Heymann M.F., Robillard N., Kraeber-Bodéré F., et al. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer 2002, 1202-1209.
10. Sanderson R.D., Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 2008, 25:149-159.
11. Cherel M., Gouard S., Gaschet J., Sai-Maurel C., Bruchertseifer F., Morgenstern A., et al. 213Bi Radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med 2013, 54:1597-1604.
12. Onishi M., Kinoshita S., Morikawa Y., Shibuya A., Phillips J., Lanier L.L., et al. Applications of retrovirus-mediated expression cloning. Exp Hematol 1996, 24:324-329.
13. Klerk C., Overmeer R., Niers T., Versteeg H., Richel D., Buckle T., et al. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques 2007, 43:S7-S30.
14. Chaplin D.J., Acker B., Olive P.L. Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys 1989, 16:1131-1135.
15. Kulkarni S.S., Leventon G.S., Huynh L., Chow H., Dicke K.A., Zander A.R. Effect of pretreatment with cyclophosphamide on high-dose toxicity of melphalan in mice. Cancer Res 1985, 45:5431-5435.
16. Kuehl W.M., Bergsagel P.L. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am Soc Hematol Educ Program 2005, 346-352.
17. Bergsagel P.L., Kuehl W.M. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005, 23:6333-6338.
18. Raab M.S., Podar K., Breitkreutz I., Richardson P.G., Anderson K.C. Multiple myeloma. Lancet 2009, 374:324-339.
19. Nair B., van Rhee F., Shaughnessy J.D., Anaissie E., Szymonifka J., Hoering A., et al. Superior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010, 115:4168-4173.
20. Michallet M., Sobh M., El-Cheikh J., Morisset S., Sirvent A., Reman O., et al. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation. Exp Hematol 2013, 1-25.
21. Cheson B.D., Leonard J.P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008, 359:613-626.
22. Morschhauser F., Kraeber-Bodere F., Wegener W.A., Harousseau J.L., Petillon M.O., Huglo D., et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol 2010, 28:3709-3716.
23. Cherel M., Davodeau F., Kraeber-Bodere F., Chatal J.F. Current status and perspectives in alpha radioimmunotherapy. Q J Nucl Med Mol Imaging 2006, 50:322-329.
24. Chouin N., Bernardeau K., Davodeau F., Cherel M., Faivre-Chauvet A., Bourgeois M., et al. Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. I. Presentation and validation of a microdosimetric model. Radiat Res 2009, 171:657-663.
25. Rousseau C., Ferrer L., Supiot S., Bardies M., Davodeau F., Faivre-Chauvet A., et al. Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumour Biol 2012, 33:679-688.
26. Supiot S., Gouard S., Charrier J., Apostolidis C., Chatal J.-F., Barbet J., et al. Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res 2005, 7047s-7052s.
27. Supiot S., Thillays F., Rio E., Gouard S., Morgenstern A., Bruchertseifer F., et al. Gemcitabine radiosensitizes multiple myeloma cells to low let, but not high let, irradiation. Radiother Oncol 2007, 97-101.
28. Hayun M., Saida H., Albeck M., Peled A., Haran-Ghera N., Sredni B. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model. Experimental Hematology 2009, 593-603. ISEH - Society for Hematology and Stem Cells.
29. Surget S., Chiron D., Gomez-Bougie P., Descamps G., Menoret E., Bataille R., et al. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res 2012, 4562-4573.
30. Jourdan M., Ferlin M., Legouffe E., Horvathova M., Liautard J., Rossi J.F., et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 1998, 637-646.
31. Buchmann I., Meyer R.G., Mier W., Haberkorn U. Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity?. Eur J Nucl Med Mol Imaging 2009, 36:484-498.
32. Bethge W.A., Wilbur D.S., Storb R., Hamlin D.K., Santos E.B., Brechbiel M.W., et al. Radio- immunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell trans- plantation in dogs: a dose deescalation study. Transplantation 2004, 78:352-359.
33. Sandmaier B.M., Bethge W.A., Wilbur D.S., Hamlin D.K., Santos E.B., Brechbiel M.W., et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 2002, 100:318-326.
34. Nakamae H., Wilbur D.S., Hamlin D.K., Thakar M.S., Santos E.B., Fisher D.R., et al. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the -emitting radionuclides Bismuth-213 or Astatine-211. Cancer Res 2009, 69:2408-2415.